STACKDSTACKDResearch
Sign up

Compound library

Peptides

Deep profiles for diligence, not product pages. Filter by goal or open any profile for mechanism, evidence, and citations.

45 compounds catalogued

Filter by goal

Showing 8 peptides tagged Metabolic.

Retatrutide

Stronger clinical signal

An investigational triple agonist (GLP-1, GIP, and glucagon receptors) studied for obesity and metabolic disease. Currently the highest-profile name in the space, widely framed as the next-generation successor to tirzepatide, with heavy search interest among fitness audiences.

Fat loss · Metabolic

Semaglutide

Stronger clinical signal

A GLP-1 receptor agonist (marketed as Ozempic, Wegovy, and Rybelsus) with robust clinical evidence for glycemic control and weight management. The molecule that mainstreamed this category and a reference point for understanding incretin-based approaches discussed in fitness communities.

Fat loss · Metabolic

Tirzepatide

Stronger clinical signal

A dual GIP/GLP-1 receptor agonist (marketed as Mounjaro and Zepbound) with extensive clinical data in type 2 diabetes and obesity. Frequently compared head-to-head with semaglutide in conversations about metabolic peptides and body recomposition.

Fat loss · Metabolic

Cagrilintide

Stronger clinical signal

A long-acting amylin-receptor analogue from Novo Nordisk, studied alone and paired with semaglutide (as "CagriSema") for weight management and type 2 diabetes. Currently one of the most-discussed "next after tirzepatide/retatrutide" names in metabolic-peptide circles.

Metabolic · Fat loss

Survodutide

Stronger clinical signal

A Boehringer Ingelheim glucagon-receptor/GLP-1-receptor dual agonist in late-stage development for obesity and MASH (fatty liver disease). Part of the current wave of multi-receptor peptides competing with tirzepatide and retatrutide for the metabolic-peptide spotlight.

Metabolic · Fat loss

Tesamorelin

Stronger clinical signal

A synthetic GHRH analogue with an approved indication for reducing excess abdominal fat in specific HIV-associated lipodystrophy contexts, often referenced when discussing visceral fat and GH axis research.

Fat loss · Muscle / GH axis · Metabolic

MOTS-c

Emerging

A mitochondria-derived peptide researched for metabolic regulation and exercise-related stress responses. Still early relative to incretin drugs, but frequently searched in biohacking circles.

Metabolic · Fat loss · Recovery · Longevity / aging

5-Amino-1MQ

Emerging

A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in fat-cell metabolism and NAD+ regulation. Reduced fat mass in diet-induced-obese mice without affecting food intake, but has never been tested in a published human clinical trial.

Fat loss · Metabolic · Longevity / aging

Evidence labels

  • EmergingMostly preclinical or early signals; human athletic data is thin.
  • Limited human dataSome human pharmacology or small studies; outcomes for fitness use remain limited.
  • Stronger clinical signalSupported by larger clinical trials in defined medical populations.

Anodized by evidence strength: blue = stronger clinical/human data, violet = limited human data or mechanism, steel = emerging/anecdotal, and amber = an in-house STACKD summary.